SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-19-193291
Filing Date
2019-07-12
Accepted
2019-07-12 17:06:03
Documents
1
Group Members
QVT ASSOCIATES GP LLCQVT FINANCIAL GP LLCQVT FINANCIAL INVESTMENT CAYMAN LTD.

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 4 TO SCHEDULE 13D d765485dsc13da.htm SC 13D/A 75506
  Complete submission text file 0001193125-19-193291.txt   77433
Mailing Address 444 MADISON AVENUE 21ST FLOOR NEW YORK NY 10022
Business Address 444 MADISON AVENUE 21ST FLOOR NEW YORK NY 10022 212-705-8800
QVT Financial LP (Filed by) CIK: 0001290162 (see all company filings)

IRS No.: 113694008 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address 11 TIMES SQUARE 33RD FLOOR NEW YORK NY 10036
Business Address 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FLOOR LONDON X0 SW1Y 4LB 44 203 318 9708
Axovant Gene Therapies Ltd. (Subject) CIK: 0001636050 (see all company filings)

IRS No.: 981333697 | Fiscal Year End: 0331
Type: SC 13D/A | Act: 34 | File No.: 005-88883 | Film No.: 19953514
SIC: 2834 Pharmaceutical Preparations